
C2N Diagnostics Launches New Plasma Aβ Multi-Analyte Assay to Advance Alzheimer’s Disease Research and Drug Development
C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, has announced the launch of a novel plasma multi-analyte assay (MAA) designed to measure amyloid beta (Aβ) protein variants using high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS). The new test, named C2N-Aβ-MAA (6x), is designed to provide researchers with detailed information about amyloid beta biology by accurately quantifying six different Aβ peptide variants from a single blood plasma sample.
The launch represents an important development in C2N Diagnostics’ efforts to advance biomarker technologies for Alzheimer’s disease and other neurodegenerative conditions. By measuring multiple amyloid beta peptide variants simultaneously, the assay is intended to provide clinical researchers and biopharmaceutical companies with additional tools to investigate amyloid processing, evaluate investigational treatments, and improve understanding of biological changes associated with neurological diseases.
The six amyloid beta variants measured by the C2N-Aβ-MAA (6x) assay include Aβ37, Aβ38, Aβ39, Aβ40, Aβ42, and Aβ43. These peptides represent different forms of amyloid beta protein that are generated through the processing of amyloid precursor protein.
The ability to measure all six variants using one plasma sample preparation is expected to improve testing efficiency while generating a broader picture of amyloid-related biological activity.
C2N believes the assay could become a valuable research tool for biopharmaceutical companies developing treatments that target amyloid beta processing, particularly therapies designed to influence the activity of enzymes involved in the production of different Aβ peptide forms.
The new plasma assay is currently available for research use only and complements the company’s existing Aβ-MAA (6x) assay developed for cerebrospinal fluid (CSF) samples.
Measuring Six Amyloid Beta Variants From a Single Blood Sample
Amyloid beta is an important biological target in Alzheimer’s disease research. The protein is produced through the processing of amyloid precursor protein, and different amyloid beta peptide variants can be generated depending on the specific pathways involved in this process.
Some amyloid beta forms, particularly Aβ42, have been extensively investigated because of their association with amyloid plaque formation in the brain. However, understanding Alzheimer’s disease biology requires more than measuring a single peptide variant.
The relative levels and patterns of different amyloid beta peptides may provide additional information about the biological mechanisms involved in amyloid production and processing.
C2N-Aβ-MAA (6x) is designed to measure six distinct peptide variants, allowing researchers to evaluate a broader range of amyloid beta-related changes.
The assay quantifies:
- Aβ37: A shorter amyloid beta peptide variant involved in amyloid processing research.
- Aβ38: A peptide variant that can provide information about amyloid precursor protein processing pathways.
- Aβ39: Another shorter amyloid beta form relevant to understanding changes in peptide production.
- Aβ40: A commonly measured amyloid beta peptide used in Alzheimer’s disease biomarker research.
- Aβ42: A longer amyloid beta peptide extensively studied for its role in amyloid accumulation and plaque formation.
- Aβ43: A longer peptide variant that may provide additional information about amyloid processing and biological activity.
By measuring these six variants together, the assay is intended to help researchers investigate changes in amyloid beta production and processing more comprehensively.
The use of high-resolution mass spectrometry allows the platform to distinguish and quantify individual peptide variants with a high level of analytical specificity.
Importantly, the assay uses a single sample preparation to measure all six variants, reducing the need for separate analytical procedures for each peptide.
This approach may offer practical advantages for clinical research programmes that require repeated biomarker measurements across multiple study participants and treatment time points.
Supporting Clinical Trials for Alzheimer’s Disease Treatments
One of the primary applications of the new assay is expected to be in biopharmaceutical clinical development.
Pharmaceutical companies are increasingly investigating treatments designed to modify the biological processes associated with Alzheimer’s disease. These approaches include therapies targeting amyloid beta production, aggregation, clearance, and other mechanisms involved in neurodegeneration.
As clinical research advances, the ability to measure treatment-related changes in specific biomarkers is becoming increasingly important.
C2N believes its C2N-Aβ-MAA (6x) assay can support clinical trials by providing researchers with more detailed information about amyloid beta biology.
Measuring multiple Aβ peptide variants may help investigators determine how experimental treatments influence amyloid processing pathways.
For example, some investigational therapies are designed to modify the activity of gamma-secretase, an enzyme involved in the production of amyloid beta peptides.
Gamma-secretase modulators are being investigated for their ability to alter the distribution of different amyloid beta peptide lengths rather than simply reducing the overall production of amyloid beta.
These treatments may influence the production of shorter and longer peptide variants, potentially changing the overall amyloid beta profile.
By measuring Aβ37, Aβ38, Aβ39, Aβ40, Aβ42, and Aβ43 simultaneously, researchers may be able to observe these changes in greater detail.
The assay could therefore support the evaluation of pharmacodynamic responses, which involve measuring biological changes resulting from exposure to an investigational treatment.
This information may help researchers understand whether a drug is producing its intended biological effect and how different doses influence amyloid processing.
Such measurements could also contribute to dose-selection strategies during clinical development.
By providing a broader view of amyloid beta peptide profiles, C2N aims to support more informed assessments of investigational therapies and help biopharmaceutical developers better characterize treatment responses.
Advancing Research Into Gamma-Secretase Modulators
Gamma-secretase is an enzyme complex involved in processing amyloid precursor protein and generating amyloid beta peptides of different lengths.
The production of these peptide variants is an important area of investigation in Alzheimer’s disease research because changes in peptide composition may influence amyloid accumulation and related biological processes.
Traditional biomarker approaches may focus on measuring selected amyloid beta forms, but evaluating multiple peptide variants can provide additional information about the underlying processing mechanisms.
The C2N-Aβ-MAA (6x) assay is designed to support this type of research by quantifying six different amyloid beta variants from one plasma sample.
For clinical studies evaluating gamma-secretase modulators, researchers may use the assay to investigate whether treatment changes the relative production of shorter and longer Aβ peptides.
These measurements could help researchers characterize the pharmacological effects of investigational drugs and understand how treatment influences amyloid precursor protein processing.
The information may also support comparisons between different treatment doses and help investigators identify biomarker patterns associated with specific pharmacological responses.
Although the assay is not intended to establish clinical treatment decisions, its research applications could contribute to a more detailed understanding of amyloid-related mechanisms and support the development of future Alzheimer’s disease therapies.
Exploring Potential Relationships With Amyloid-Related Imaging Abnormalities
Another potential research application identified by C2N involves investigating relationships between amyloid beta peptide profiles and amyloid-related imaging abnormalities (ARIA).
ARIA refers to imaging abnormalities that can occur in some patients receiving amyloid-targeting treatments for Alzheimer’s disease.
These abnormalities generally include two major categories: ARIA-E, associated with brain edema or effusion, and ARIA-H, associated with microhemorrhages or other signs of bleeding.
ARIA has become an important consideration in the development and use of certain anti-amyloid therapies.
Researchers are therefore interested in identifying biological factors that may help explain why some patients develop these imaging abnormalities during treatment.
C2N believes the new multi-analyte assay may support exploratory research examining whether specific amyloid beta peptide profiles are associated with ARIA-related outcomes.
By measuring multiple peptide variants, researchers may be able to investigate potential relationships between amyloid processing patterns and imaging findings in clinical trial participants.
This could provide additional information for understanding the biological effects of amyloid-targeting therapies.
However, these applications remain exploratory. The company has not announced that the assay can predict ARIA risk or independently determine whether a patient will experience treatment-related imaging abnormalities.
Instead, the potential value lies in supporting further research into the biological mechanisms associated with amyloid-targeting treatments.
High-Resolution Mass Spectrometry Provides Advanced Biomarker Measurement
The C2N-Aβ-MAA (6x) assay uses liquid chromatography-tandem mass spectrometry, a sophisticated analytical technology widely used in biomarker research and clinical laboratory applications.
LC-MS/MS combines liquid chromatography with mass spectrometry to separate, identify, and quantify specific molecules within biological samples.
In the context of amyloid beta testing, the technology enables researchers to distinguish different peptide variants based on their molecular characteristics.
High-resolution mass spectrometry is particularly valuable when studying proteins and peptides that may have closely related structures.
By applying this technology to plasma samples, C2N aims to provide researchers with a detailed assessment of multiple amyloid beta peptide forms.
The new assay also builds on the company’s existing experience in developing mass spectrometry-based biomarkers for neurological conditions.
Its ability to measure six Aβ variants through one sample preparation is intended to streamline the analytical process and provide additional value for clinical research programmes.
The availability of a plasma-based assay also complements the company’s existing CSF-based Aβ-MAA (6x) testing capability.
Together, these technologies provide research teams with additional options for investigating amyloid beta biology using different biological sample types.
C2N Highlights Commitment to Biomarker Innovation
Dr. Joel Braunstein, CEO and President of C2N Diagnostics, highlighted the importance of the new assay in advancing the company’s biomarker development strategy.
According to Braunstein, introducing the C2N-Aβ-MAA (6x) assay in blood demonstrates the company’s continued commitment to innovation and supporting clinical researchers working on novel treatments and diagnostic tools for neurological conditions.
He explained that the next-generation assay uses a single sample preparation to generate important insights into neurological diseases and treatments that affect brain amyloid processing.
The launch also reflects C2N’s broader objective of expanding the availability of advanced biomarker technologies that can support pharmaceutical research and improve the understanding of brain health.
The company believes that more comprehensive biomarker measurements can help clinical researchers evaluate biological responses and investigate disease-related mechanisms with greater precision.
Extensive Experience Supporting Alzheimer’s Disease Research
C2N Diagnostics has an established history of contributing biomarker technologies to clinical research programmes worldwide.
According to the company, its biomarkers have supported more than 200 clinical studies globally.
Additionally, more than 90,000 Precivity-related biomarker measurements have been reported in peer-reviewed scientific publications, with further manuscripts currently under review.
This research experience reflects the company’s ongoing involvement in developing analytical tools for Alzheimer’s disease and related neurological conditions.
C2N’s biomarker technologies have been used to support research into amyloid pathology, neurological disease mechanisms, and treatment development.
The introduction of C2N-Aβ-MAA (6x) expands these capabilities by adding a plasma-based multi-analyte research assay that measures six amyloid beta peptide variants.
The company expects this technology to complement its existing portfolio and provide additional opportunities for collaboration with biopharmaceutical developers and clinical research organisations.
Precivity Portfolio Supports Clinical Alzheimer’s Disease Assessment
Alongside its research-focused assay development, C2N Diagnostics offers the Precivity® portfolio of blood-based tests designed to support healthcare professionals in assessing Alzheimer’s disease-related biomarkers.
The clinically available product line includes PrecivityAD®, PrecivityAD2®, and Precivity-ApoE™.
These tests are designed to provide different types of information relevant to Alzheimer’s disease evaluation and treatment discussions.
PrecivityAD® and PrecivityAD2® help healthcare providers identify brain amyloid pathology associated with Alzheimer’s disease. These tests use blood-based biomarker measurements to support the assessment of amyloid-related changes in the brain.
PrecivityAD2 has received FDA clearance and is described by C2N as the first test combining high-resolution mass spectrometry with a multiple-analyte algorithmic score to aid in the diagnosis of Alzheimer’s disease.
The test represents an important development in the use of advanced blood-based biomarkers to support Alzheimer’s disease assessment.
Precivity-ApoE™ is designed to determine a patient’s ApoE proteotype. This information can help inform discussions about amyloid-related imaging abnormality risk before treatment with anti-amyloid therapies.
ApoE is a protein involved in lipid transport and other biological functions. Different ApoE proteotypes are relevant to Alzheimer’s disease research and can influence discussions about treatment-associated risks.
By offering these tests, C2N aims to provide healthcare professionals with additional biomarker information to support diagnostic evaluation and treatment planning.
The new C2N-Aβ-MAA (6x) plasma assay expands the company’s capabilities into multi-analyte amyloid research for biopharmaceutical development.
Expanding the Role of Blood-Based Biomarkers in Alzheimer’s Research
The development of blood-based biomarkers is becoming an increasingly important area in Alzheimer’s disease research and clinical development.
Historically, evaluating brain amyloid pathology has relied on methods such as positron emission tomography (PET) imaging and cerebrospinal fluid analysis.
Although these approaches provide valuable information, blood-based biomarkers offer opportunities for more accessible and potentially scalable testing.
Advanced analytical technologies, including high-resolution mass spectrometry, are helping researchers investigate specific proteins and peptide variants in blood samples.
C2N’s new assay builds on this progress by measuring six amyloid beta peptide variants simultaneously.
Its potential applications include investigating amyloid processing, evaluating pharmacodynamic responses, supporting dose-selection research, and exploring relationships between peptide profiles and treatment-associated imaging abnormalities.
The assay is currently available for research use only and is not being introduced as a clinical diagnostic test.
The launch of C2N-Aβ-MAA (6x) represents another step in C2N Diagnostics’ efforts to advance biomarker technologies for Alzheimer’s disease and related neurodegenerative conditions.
By combining high-resolution mass spectrometry with the ability to measure six amyloid beta peptide variants from a single plasma sample, the company aims to provide clinical researchers with a more comprehensive tool for studying amyloid biology.
The assay is expected to support biopharmaceutical clinical trials, particularly those investigating treatments that modify amyloid beta processing, including gamma-secretase modulators.
It may also provide opportunities to explore pharmacodynamic responses, inform dose-selection strategies, and investigate potential relationships between amyloid peptide profiles and ARIA.
Supported by its experience across more than 200 clinical studies and its established Precivity portfolio, C2N continues to expand its work in advanced brain health diagnostics and biomarker research.
Ultimately, the introduction of the plasma C2N-Aβ-MAA (6x) assay reinforces the company’s commitment to developing innovative analytical tools that support Alzheimer’s disease research, advance precision medicine approaches, and contribute to the development of future neurological treatments.
About C2N Diagnostics
C2N is a leading specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health.
C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world.
This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. Over 90,000 Precivity®-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.


